Earnings Call Summary | Cytosorbents(CTSO.US) Q1 2024 Earnings Conference
Earnings Call Summary | Cytosorbents(CTSO.US) Q1 2024 Earnings Conference
The following is a summary of the Cytosorbents Corporation (CTSO) Q1 2024 Earnings Call Transcript:
以下是细胞吸附剂公司（CTSO）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Cytosorbents Corporation experienced a 14% increase in product sales in Q1 2024, rising from $7.9 million to $9 million. Additionally, a 22% sequential increase was reported from Q4 2023.
The company saw an increase in product gross margins to 76%, an improvement from the previous year's 68% in Q1.
By the end of Q1, the company had $10.1 million in cash, including $1.5 million in restricted cash, which is expected to cover operations into Q4 2024.
Total product sales for this quarter were mainly driven by developments in direct sales in Europe and multiple distributor countries.
2024年第一季度，Cytosorbents Corporation的产品销售额增长了14％，从790万美元增至900万美元。此外，据报道，自2023年第四季度以来，连续增长了22％。
该公司的产品毛利率增长至76％，较去年第一季度的68％有所改善。
截至第一季度末，该公司拥有1,010万澳元的现金，其中包括150万澳元的限制性现金，预计将涵盖2024年第四季度的运营。
本季度的产品总销售主要是由欧洲和多个分销国直销的发展推动的。
Business Progress:
业务进展：
Cytosorbents presented its STAR-T data at the American Association for Thoracic Surgery. It is preparing to submit marketing applications for the DrugSorb-ATR system to FDA and Health Canada in Q3.
The company had delivered over 237,000 devices by Q1 and plans to reach a quarter of a million devices by year's end.
Introduction of the PuriFi hemoperfusion pump is planned in selected international countries. Positive customer response has been reported on new data on CytoSorb in acute liver disease, heart transplant, and septic shock.
Regulatory submission preparation is at an advanced stage, aided by productive interactions with the FDA. Initiatives continue to reach new customer groups and expand indications.
Company anticipates PuriFi system will drive sales of CytoSorb devices, especially in regions with fewer dialysis infrastructures. Submissions for DrugSorb to FDA and Health Canada are planned regardless of the distinct approval timelines of both entities.
Cytosorbents在美国胸外科学会上公布了其STAR-T数据。它正准备在第三季度向美国食品药品管理局和加拿大卫生部提交DrugSorb-ATR系统的上市申请。
截至第一季度，该公司已交付超过23.7万台设备，并计划到年底达到25万台设备。
计划在部分国际国家推出PuriFi血液灌注泵。根据CytoSorb在急性肝病、心脏移植和感染性休克中的新数据，客户反应良好。
在与美国食品和药物管理局富有成效的互动的帮助下，监管申报准备工作已进入后期阶段。各项举措继续覆盖新的客户群体，并扩大了覆盖范围。
该公司预计，PuriFi系统将推动CytoSorb设备的销售，尤其是在透析基础设施较少的地区。无论两个实体的批准时间表有何不同，都计划向美国食品药品管理局和加拿大卫生部提交DrugSorb的申请。
More details: Cytosorbents IR
更多详情： 细胞吸附剂 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。